EBYMECT XR

Prezentare produs

About EBYMECT XR

EBYMECT XR is a prescription medicine formulated as an extended-release tablet designed to assist in the management of blood glucose levels. This medication is intended for use in adult patients as a therapeutic option to support glycemic control. It is classified as a combination therapy, integrating two distinct pharmacological agents into a single oral dosage form to streamline treatment regimens for individuals diagnosed with type 2 diabetes mellitus. Patients should always follow the specific administration instructions provided by their healthcare professional to ensure the medication is used safely and effectively.

Key Benefits & Uses

• Provides a combined therapeutic approach for the management of type 2 diabetes.
• Utilizes an extended-release delivery system for consistent medication distribution.
• Supports the maintenance of target blood sugar levels when used alongside diet and exercise.

Active Ingredient & Action

EBYMECT XR contains two active pharmaceutical ingredients: dapagliflozin propanediol and metformin hydrochloride. Dapagliflozin functions by inhibiting the sodium-glucose cotransporter 2 in the kidneys, which promotes the excretion of glucose through urine. Metformin hydrochloride works primarily by reducing the amount of glucose produced by the liver and improving the body's sensitivity to insulin.

Important Notes

This medication must be used strictly under the supervision of a qualified medical practitioner. It is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis. Always store the product in its original packaging at room temperature, away from moisture and heat. Consult your doctor or pharmacist if you have questions regarding potential drug interactions or specific health conditions.